CI

At a glance

ClinicalIndex Comparison Record
Phase 2Recruiting· 218 target
Drug / intervention
HS-20093 for Injection +5 moredrug
Likely dose
Not stated in record
Key inclusion· 8
  • ✓Aged 18 to 80 years (inclusive), male
  • ✓ECOG performance status of 0 or 1
  • ✓Expected survival time ≥12 weeks
  • ✓Histologically or cytologically confirmed prostate adenocarcinoma, with no features of neuroendocrine carcinoma or small cell carcinoma
Key exclusion· 17
  • ✕Known hypersensitivity or intolerance to investigational drug(s) or excipients
  • ✕Adverse events from prior anti-tumor therapy not recovered to Grade ≤1 (CTCAE v5.0)
  • ✕Estrogen, progesterone, or 5-alpha reductase inhibitors within 28 days prior to enrollment
  • ✕Herbal medicines with anti-prostate cancer or PSA-lowering effects within 14 days prior to enrollment

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT07230106
NCT07230106Phase 2RecruitingHigh MomentumUpdated 3mo ago
CompareCT.gov

A Phase II Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetic Characteristics, and Efficacy of HS-20093 or SHR2554 Tablets in Combination With Novel Hormonal Agents in Participants With Metastatic Prostate Cancer

Jiangsu HengRui Medicine Co., Ltd.·interventional·Posted Nov 17, 2025·Updated Mar 3, 2026

In Brief

A Phase 2 clinical trial evaluating HS-20093 for Injection, SHR3680 Tablet, and 4 other interventions for Prostate Cancer. Currently recruiting, targeting 218 participants across 2 sites.

Signals

Enrolling ahead of pace

Detailed Summary

This is a phase II, multicentre clinical study investigating HS-20093 or SHR2554 in combination with a Novel Hormonal Agent (NHA) for advanced prostate cancer. The trial comprises two cohorts.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsProstate Cancer
CountriesChina
Collaborators--

Timeline

Phase 2Recruiting
20262027202820292030
First PostedNov 17, 2025
Enrollment StartDec 8, 2025
Primary CompletionDec 1, 2028
Study CompletionDec 1, 2029
TodayJul 2, 2026
Enrollment to primary: 3.0 yearsPosted 8 months agoPrimary completion in 2.4 years

Interventions

HS-20093 for Injectiondrug

HS-20093 for injection.

SHR3680 Tabletdrug

SHR3680 tablet.

Abiraterone Tabletdrug

Abiraterone tablet.

SHR2554 Tabletdrug

SHR2554 tablet.

Enzalutamide Tabletdrug

Enzalutamide tablet.

Darotamine Capsuledrug

Darotamine capsule.